{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T15:31:53Z","timestamp":1671291113775},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,5,30]],"date-time":"2015-05-30T00:00:00Z","timestamp":1432944000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1007\/s00520-015-2777-7","type":"journal-article","created":{"date-parts":[[2015,5,29]],"date-time":"2015-05-29T09:45:34Z","timestamp":1432892734000},"page":"267-273","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Incidence of bone pain in patients with breast cancer treated with lipegfilgrastim or pegfilgrastim: an integrated analysis from phase II and III studies"],"prefix":"10.1007","volume":"24","author":[{"given":"I. M.","family":"Bondarenko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,5,30]]},"reference":[{"key":"2777_CR1","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1471-2407-11-404","volume":"11","author":"KL Cooper","year":"2011","unstructured":"Cooper KL, Madan J, Whyte S, Stevenson MD, Akehurst RL (2011) Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11:404. doi: 10.1186\/1471-2407-11-404","journal-title":"BMC Cancer"},{"issue":"suppl 5","key":"2777_CR2","doi-asserted-by":"crossref","first-page":"v248","DOI":"10.1093\/annonc\/mdq195","volume":"21","author":"J Crawford","year":"2010","unstructured":"Crawford J, Caserta C, Roila F (2010) Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications. Ann Oncol 21(suppl 5):v248\u2013v251. doi: 10.1093\/annonc\/mdq195","journal-title":"Ann Oncol"},{"key":"2777_CR3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47:8\u201332. doi: 10.1016\/j.ejca.2010.10.013","journal-title":"Eur J Cancer"},{"key":"2777_CR4","unstructured":"(2014) NCCN Clinical Practice Guidelines in Oncology. Myeloid growth factors v.2.2014. National Comprehensive Cancer Network. www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp . Accessed 23 January 2015"},{"key":"2777_CR5","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187\u20133205. doi: 10.1200\/JCO.2006.06.4451","journal-title":"J Clin Oncol"},{"key":"2777_CR6","unstructured":"Lonquex: summary of product characteristics (2013) European Medicines Agency, London, UK"},{"key":"2777_CR7","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1186\/1471-2407-13-386","volume":"13","author":"I Bondarenko","year":"2013","unstructured":"Bondarenko I, Gladkov OA, Elsaesser R, Buchner A, Bias P (2013) Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin\/docetaxel chemotherapy. BMC Cancer 13:386\u2013398. doi: 10.1186\/1471-2407-13-386","journal-title":"BMC Cancer"},{"key":"2777_CR8","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.bmt.1705722","volume":"40","author":"CC Tigue","year":"2007","unstructured":"Tigue CC, McKoy JM, Evens AM, Trifilio SM, Tallman MS, Bennett CL (2007) Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant 40:185\u2013192. doi: 10.1038\/sj.bmt.1705722","journal-title":"Bone Marrow Transplant"},{"key":"2777_CR9","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2013.08.006","volume":"89","author":"M Lambertini","year":"2013","unstructured":"Lambertini M, Del Mastro L, Bellodi A, Pronzato P (2013) The five \u201cWs\u201d for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs). Crit Rev Oncol Hematol 89:112\u2013128. doi: 10.1016\/j.critrevonc.2013.08.006","journal-title":"Crit Rev Oncol Hematol"},{"key":"2777_CR10","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1093\/annonc\/mdf130","volume":"13","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, Jones SE, O\u2019Shaughnessy J et al (2002) Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol 13:903\u2013909","journal-title":"Ann Oncol"},{"key":"2777_CR11","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20:727\u2013731","journal-title":"J Clin Oncol"},{"key":"2777_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29\u201335","journal-title":"Ann Oncol"},{"key":"2777_CR13","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2011.37.8364","volume":"30","author":"JJ Kirshner","year":"2012","unstructured":"Kirshner JJ, Heckler CE, Janelsins MC et al (2012) Prevention of pegfilgrastim-induced bone pain: a phase III double-blind placebo-controlled randomized clinical trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base. J Clin Oncol 30:1974\u20131979. doi: 10.1200\/JCO.2011.37.8364","journal-title":"J Clin Oncol"},{"key":"2777_CR14","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178\u20131184. doi: 10.1200\/JCO.2005.09.102","journal-title":"J Clin Oncol"},{"key":"2777_CR15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.3816\/CBC.2003.n.003","volume":"3","author":"E Kubista","year":"2003","unstructured":"Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T (2003) Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer 3:391\u2013398","journal-title":"Clin Breast Cancer"},{"key":"2777_CR16","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1548-5315(11)70107-3","volume":"4","author":"JJ Kirshner","year":"2007","unstructured":"Kirshner JJ, Hickok J, Hofman M (2007) Pegfilgrastim-induced bond pain: incidence, risk factors, and management in a community practice. Community Oncol 4:455\u2013459","journal-title":"Community Oncol"},{"key":"2777_CR17","first-page":"S240","volume":"20","author":"A Buchner","year":"2012","unstructured":"Buchner A, Bias P, Kaufmann M, Mueller U (2012) A randomized, double-blind, active control, multicenter, dose finding study of lipegfilgrastim in breast cancer patients receiving myelosuppressive therapy [abstract 1004]. Support Care Cancer 20:S240","journal-title":"Support Care Cancer"},{"key":"2777_CR18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-014-3120-6","volume":"148","author":"A Buchner","year":"2014","unstructured":"Buchner A, Elsasser R, Bias P (2014) A randomized, double-blind, active control, multicenter, dose-finding study of lipegfilgrastim (XM22) in breast cancer patients receiving myelosuppressive therapy. Breast Cancer Res Treat 148:107\u2013116. doi: 10.1007\/s10549-014-3120-6","journal-title":"Breast Cancer Res Treat"},{"key":"2777_CR19","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1200\/JCO.2004.08.125","volume":"22","author":"E Alba","year":"2004","unstructured":"Alba E, Martin M, Ramos M et al (2004) Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol 22:2587\u20132593. doi: 10.1200\/JCO.2004.08.125","journal-title":"J Clin Oncol"},{"key":"2777_CR20","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","volume":"21","author":"JM Nabholtz","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968\u2013975","journal-title":"J Clin Oncol"},{"key":"2777_CR21","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1159\/000319693","volume":"33","author":"CF Waller","year":"2010","unstructured":"Waller CF, Semiglazov VF, Tjulandin S, Bentsion D, Chan S, Challand R (2010) A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 33:504\u2013511. doi: 10.1159\/000319693","journal-title":"Onkologie"},{"key":"2777_CR22","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1185\/030079907X219599","volume":"23","author":"L Pinto","year":"2007","unstructured":"Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G (2007) Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin 23:2283\u20132295. doi: 10.1185\/030079907X219599","journal-title":"Curr Med Res Opin"},{"key":"2777_CR23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CAD.0b013e328011a532","volume":"18","author":"N Andre","year":"2007","unstructured":"Andre N, El Kababri M, Bertrand P et al (2007) Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy. Anticancer Drugs 18:277\u2013281. doi: 10.1097\/CAD.0b013e328011a532","journal-title":"Anticancer Drugs"},{"key":"2777_CR24","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2354.2008.00959.x","volume":"18","author":"D Almenar","year":"2009","unstructured":"Almenar D, Mayans J, Juan O et al (2009) Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain\u2014results of the LEARN Study. Eur J Cancer Care 18:280\u2013286. doi: 10.1111\/j.1365-2354.2008.00959.x","journal-title":"Eur J Cancer Care"},{"key":"2777_CR25","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1200\/JCO.2006.08.8823","volume":"25","author":"NM Kuderer","year":"2007","unstructured":"Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158\u20133167. doi: 10.1200\/JCO.2006.08.8823","journal-title":"J Clin Oncol"},{"key":"2777_CR26","doi-asserted-by":"crossref","unstructured":"Volovat C, Bondarenko IM, Gladkov OA, et al (2015) Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non\u2013small cell lung cancer receiving myelosuppressive therapy. SpringerPlus: in press","DOI":"10.1186\/s40064-015-1067-7"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2777-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-015-2777-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-015-2777-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T02:09:42Z","timestamp":1559095782000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-015-2777-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["2777"],"URL":"https:\/\/doi.org\/10.1007\/s00520-015-2777-7","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,5,30]]}}}